Search

Your search keyword '"Ilariucci, Fiorella"' showing total 336 results
Start Over Author "Ilariucci, Fiorella"
336 results on '"Ilariucci, Fiorella"'

1. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

Author

Chiappella, Annalisa, Dodero, Anna, Evangelista, Andrea, Re, Alessandro, Orsucci, Lorella, Usai, Sara Veronica, Castellino, Claudia, Stefoni, Vittorio, Pinto, Antonio, Zanni, Manuela, Ciancia, Rosanna, Ghiggi, Chiara, Rossi, Francesca Gaia, Arcari, Annalisa, Ilariucci, Fiorella, Zilioli, Vittorio Ruggero, Flenghi, Leonardo, Celli, Melania, Volpetti, Stefano, Benedetti, Fabio, Ballerini, Filippo, Musuraca, Gerardo, Bruna, Riccardo, Patti, Caterina, Leonardi, Francesco, Arcaini, Luca, Magagnoli, Massimo, Cavallo, Federica, Bermema, Anisa, Tucci, Alessandra, Boccomini, Carola, Ciccone, Giovannino, Carniti, Cristiana, Pileri, Stefano Aldo, and Corradini, Paolo

Published
2023
Full Text
View/download PDF

2. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Author

Ferreri, Andrés J. M., Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P., Schorb, Elisabeth, Celico, Claudia, Falautano, Monica, Nonis, Alessandro, La Rosée, Paul, Binder, Mascia, Fabbri, Alberto, Ilariucci, Fiorella, Krampera, Mauro, Roth, Alexander, Hemmaway, Claire, Johnson, Peter W., Linton, Kim M., Pukrop, Tobias, Gørløv, Jettes Sønderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jense, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Zanni, Manuela, Krause, Stefan W., Schmoll, Hans J., Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Thurner, Lorenz, Cabras, Giuseppina, Pennese, Elsa, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Jurgen, Ferranti, Antonella, Cozens, Kelly, Burger, Elvira, Ielmini, Nicoletta, Cavalli, Franco, Zucca, Emanuele, and Illerhaus, Gerald

Published
2022
Full Text
View/download PDF

3. MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

Author

Ferreri, Andrés J M, Doorduijn, Jeanette K, Re, Alessandro, Cabras, Maria Giuseppina, Smith, Jeffery, Ilariucci, Fiorella, Luppi, Mario, Calimeri, Teresa, Cattaneo, Chiara, Khwaja, Jahanzaib, Botto, Barbara, Cellini, Claudia, Nassi, Luca, Linton, Kim, McKay, Pam, Olivieri, Jacopo, Patti, Caterina, Re, Francesca, Fanni, Alessandro, Singh, Vikram, Bromberg, Jacoline E C, Cozens, Kelly, Gastaldi, Elisabetta, Bernardi, Massimo, Cascavilla, Nicola, Davies, Andrew, Fox, Christopher P, Frezzato, Maurizio, Osborne, Wendy, Liberati, Anna Marina, Novak, Urban, Zambello, Renato, Zucca, Emanuele, and Cwynarski, Kate

Published
2021
Full Text
View/download PDF

4. Atypical Presentation of Invasive Aspergillosis during Treatment with Mogamulizumab.

Author

Pavone, Paolo, Arletti, Laura, Ilariucci, Fiorella, Albano, Tommaso, Lusetti, Deborah, Corsini, Romina, Merli, Francesco, and Mezzadri, Sergio

Subjects
PULMONARY aspergillosis, IMMUNE reconstitution inflammatory syndrome, MYCOSIS fungoides, DISEASE progression, PULMONARY nodules
Abstract

Treatment with CCR-4 antagonists has been shown to be protective against the development of invasive pulmonary aspergillosis in animal models. Herein, we present a case of fatal invasive pulmonary aspergillosis in a patient receiving Mogamulizumab. A 64-year-old man with refractory mycosis fungoides was found to have diffuse bilateral pulmonary nodules during a chest CT in June 2022. Bronchoalveolar lavage (BAL) fungal and bacterial cultures and galactomannan were negative, as well as serum beta-glucan and galactomannan. Histology showed a lymphoid infiltrate with a negative fungal stain, so a presumptive diagnosis of lymphoma infiltration was made, and the patient started the CCR-4 antagonist Mogamulizumab treatment in August 2022. He had no symptoms until November when he presented to the hematology clinic reporting dyspnea. He had neutrophilic leukocytosis (18.610 cells/µL), his c-reactive protein was 27 mg/dL, and his skin lesions from mycosis fungoides were just starting to improve. A CT scan showed large diffuse bilateral severely necrotic cavitated lesions with thick walls and apparently synchronous evolution. Beta-glucan was 31 pg/mL (wako method), while serum galactomannan 3.6. BAL was positive for Aspergillus fumigatus culture and galactomannan. Patient started voriconazole but, despite being in a stable condition, he suddenly died after two days. Discussion: Paradoxically, worsening of the chronic pulmonary aspergillosis has been reported after nivolumab treatment, and immune reconstitution syndromes are usually seen during neutrophil recovery after intensive chemotherapy. Our patient already presented indolent lung lesions from 5 months before and he remained completely asymptomatic until the aspergillosis diagnosis when he quickly passed away. Even if a progression of the lesions was expected in 5 months, this case had an atypical presentation. During the 5-month period, he had no pulmonary symptoms, and his c-reactive protein was negative. Furthermore, in the setting of the natural progression of subacute/chronic aspergillosis, a different radiological picture was expected with a less severe and probably asynchronous evolution. We think that the immune restoration associated with Mogamulizumab (also supported by the concurrent clinical response of the skin lesions) could have been detrimental in this case, exacerbating a catastrophic immune response or alternatively masquerading the clinical progression of aspergillosis. Clinicians should be aware of immune reconstitution syndromes possibly leading to fatal outcomes in immunocompromised patients starting CCR-4 antagonists. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Author

Ferreri, Andrés J M, Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P, Schorb, Elisabeth, La Rosée, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire, Johnson, Peter, Linton, Kim M, Pukrop, Tobias, Sønderskov Gørløv, Jette, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W, Schmoll, Hans J, Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S, Finke, Jürgen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, and Illerhaus, Gerald

Published
2017
Full Text
View/download PDF

6. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials

Author

Gentile, Massimo, Zirlik, Katja, Ciolli, Stefania, Mauro, Francesca R., Di Renzo, Nicola, Mastrullo, Lucia, Angrilli, Francesco, Molica, Stefano, Tripepi, Giovanni, Giordano, Annamaria, Di Raimondo, Francesco, Selleri, Carmine, Coscia, Marta, Musso, Maurizio, Orsucci, Lorella, Mannina, Donato, Rago, Angela, Giannotta, Angela, Ferrara, Felicetto, Herishanu, Yair, Shvidel, Lev, Tadmor, Tamar, Scortechini, Ilaria, Ilariucci, Fiorella, Murru, Roberta, Guarini, Attilio, Musuraca, Gerardo, Mineo, Giuseppe, Vincelli, Iolanda, Arcari, Annalisa, Tarantini, Giuseppe, Caparrotti, Giuseppe, Chiarenza, Annalisa, Levato, Luciano, Villa, Maria Rosaria, De Paolis, Maria Rosaria, Zinzani, Pier Luigi, Polliack, Aaron, and Morabito, Fortunato

Published
2016
Full Text
View/download PDF

7. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

8. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Mauro, Francesca Romana, additional, Laurenti, Luca, additional, Reda, Gianluigi, additional, Moia, Riccardo, additional, Condoluci, Adalgisa, additional, Vincelli, Iolanda, additional, Chiarenza, Annalisa, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mezzatesta, Sabrina, additional, Laureana, Roberta, additional, Cutrona, Giovanna, additional, Di Raimondo, Francesco, additional, Fronza, Gilberto, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Rossi, Francesca Maria, additional, Olivieri, Jacopo, additional, Zaja, Francesco, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Del Principe, Maria Ilaria, additional, Ilariucci, Fiorella, additional, Del Poeta, Giovanni, additional, Ferrarini, Manlio, additional, Neri, Antonino, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 2 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Tables 1 - 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 5 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 4 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

15. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment

Author

Morabito, Fortunato, Cutrona, Giovanna, Mosca, Laura, D’Anca, Marianna, Matis, Serena, Gentile, Massimo, Vigna, Ernesto, Colombo, Monica, Recchia, Anna Grazia, Bossio, Sabrina, De Stefano, Laura, Maura, Francesco, Manzoni, Martina, Ilariucci, Fiorella, Consoli, Ugo, Vincelli, Iolanda, Musolino, Caterina, Cortelezzi, Agostino, Molica, Stefano, Ferrarini, Manlio, and Neri, Antonino

Published
2015
Full Text
View/download PDF

16. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

17. The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Author

Chiappella, Annalisa, primary, Dodero, Anna, additional, Evangelista, Andrea, additional, Re, Alessandro, additional, Orsucci, Lorella, additional, Usai, Sara Veronica, additional, Castellino, Claudia, additional, Stefoni, Vittorio, additional, Pinto, Antonio, additional, Zanni, Manuela, additional, Ciancia, Rosanna, additional, Ghiggi, Chiara, additional, Rossi, Francesca Gaia, additional, Arcari, Annalisa, additional, Ilariucci, Fiorella, additional, Zilioli, Vittorio Ruggero, additional, Flenghi, Leonardo, additional, Celli, Melania, additional, Volpetti, Stefano, additional, Benedetti, Fabio, additional, Ballerini, Filippo, additional, Musuraca, Gerardo, additional, Bruna, Riccardo, additional, Patti, Caterina, additional, Leonardi, Francesco, additional, Arcaini, Luca, additional, Magagnoli, Massimo, additional, Cavallo, Federica, additional, Tabanelli, Valentina, additional, Ciccone, Giovannino, additional, Pileri, Stefano A, additional, and Corradini, Paolo, additional

Published
2022
Full Text
View/download PDF

18. Primary Vitreoretinal Lymphoma: Current Diagnostic Laboratory Tests and New Emerging Molecular Tools

Author

Melli, Beatrice, primary, Gentile, Pietro, additional, Nicoli, Davide, additional, Farnetti, Enrico, additional, Croci, Stefania, additional, Gozzi, Fabrizio, additional, Bolletta, Elena, additional, De Simone, Luca, additional, Sanguedolce, Francesca, additional, Palicelli, Andrea, additional, Zizzo, Maurizio, additional, Ricci, Stefano, additional, Ilariucci, Fiorella, additional, Rossi, Cristiana, additional, Cavazza, Alberto, additional, Ascani, Stefano, additional, Cimino, Luca, additional, and Zanelli, Magda, additional

Published
2022
Full Text
View/download PDF

19. Artificial Intelligence-Assisted Processing of Anterior Segment OCT Images in the Diagnosis of Vitreoretinal Lymphoma.

Author

Gozzi, Fabrizio, Bertolini, Marco, Gentile, Pietro, Verzellesi, Laura, Trojani, Valeria, De Simone, Luca, Bolletta, Elena, Mastrofilippo, Valentina, Farnetti, Enrico, Nicoli, Davide, Croci, Stefania, Belloni, Lucia, Zerbini, Alessandro, Adani, Chantal, De Maria, Michele, Kosmarikou, Areti, Vecchi, Marco, Invernizzi, Alessandro, Ilariucci, Fiorella, and Zanelli, Magda

Subjects
OPTICAL coherence tomography, RECEIVER operating characteristic curves, CANCER diagnosis, IRIDOCYCLITIS
Abstract

Anterior segment optical coherence tomography (AS-OCT) allows the explore not only the anterior chamber but also the front part of the vitreous cavity. Our cross-sectional single-centre study investigated whether AS-OCT can distinguish between vitreous involvement due to vitreoretinal lymphoma (VRL) and vitritis in uveitis. We studied AS-OCT images from 28 patients (11 with biopsy-proven VRL and 17 with differential diagnosis uveitis) using publicly available radiomics software written in MATLAB. Patients were divided into two balanced groups: training and testing. Overall, 3260/3705 (88%) AS-OCT images met our defined quality criteria, making them eligible for analysis. We studied five different sets of grey-level samplings (16, 32, 64, 128, and 256 levels), finding that 128 grey levels performed the best. We selected the five most effective radiomic features ranked by the ability to predict the class (VRL or uveitis). We built a classification model using the xgboost python function; through our model, 87% of eyes were correctly diagnosed as VRL or uveitis, regardless of exam technique or lens status. Areas under the receiver operating characteristic curves (AUC) in the 128 grey-level model were 0.95 [CI 0.94, 0.96] and 0.84 for training and testing datasets, respectively. This preliminary retrospective study highlights how AS-OCT can support ophthalmologists when there is clinical suspicion of VRL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)

Author

Zallio, Francesco, Tamiazzo, Stefania, Monagheddu, Chiara, Merli, Francesco, Ilariucci, Fiorella, Stelitano, Caterina, Liberati, Anna Marina, Mannina, Donato, Vitolo, Umberto, Angelucci, Emanuele, Scalabrini, Delia Rota, Vallisa, Daniele, Bellei, Monica, Bari, Alessia, Ciccone, Giovannino, Salvi, Flavia, and Levis, Alessandro

Published
2016
Full Text
View/download PDF

24. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

Author

Mauro, Francesca Romana, primary, Paoloni, Francesca, additional, Molica, Stefano, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Sportoletti, Paolo, additional, Marchetti, Monia, additional, Pietrasanta, Daniela, additional, Marasca, Roberto, additional, Gaidano, Gianluca, additional, Coscia, Marta, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Di Renzo, Nicola Di, additional, Ilariucci, Fiorella, additional, Liberati, Anna Marina, additional, Orsucci, Lorella, additional, Re, Francesca, additional, Tani, Monica, additional, Musuraca, Gerardo, additional, Gottardi, Daniela, additional, Zinzani, Pier Luigi, additional, Gozzetti, Alessandro, additional, Molinari, Annalia, additional, Gentile, Massimo, additional, Chiarenza, Annalisa, additional, Laurenti, Luca, additional, Varettoni, Marzia, additional, Ibatici, Adalberto, additional, Murru, Roberta, additional, Ruocco, Valeria, additional, Del Giudice, Ilaria Del, additional, De Propris, Maria Stefania De, additional, Della Starza, Irene Della, additional, Raponi, Sara, additional, Nanni, Mauro, additional, Fazi, Paola, additional, Neri, Antonino, additional, Guarini, Anna, additional, Rigolin, Gian Matteo, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

25. Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Author

Ferreri, Andrés J M, primary, Cwynarski, Kate, additional, Pulczynski, Elisa, additional, Fox, Christopher P., additional, La Rosée, Paul, additional, Schorb, Elisabeth, additional, Krampera, Mauro, additional, Ilariucci, Fiorella, additional, Orsucci, Lorella, additional, Fabbri, Alberto, additional, Tucci, Alessandra, additional, Roeth, Alexander, additional, Linton, Kim, additional, Binder, Mascha, additional, Hemmaway, Claire, additional, Cabras, Maria Giuseppina, additional, Pinto, Antonio, additional, Calimeri, Teresa, additional, Cavalli, Franco, additional, Zucca, Emanuele, additional, and Illerhaus, Gerald, additional

Published
2021
Full Text
View/download PDF

26. Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Author

Chiappella, Annalisa, primary, Carniti, Cristiana, additional, Re, Alessandro, additional, Castellino, Claudia, additional, Evangelista, Andrea, additional, Tabanelli, Valentina, additional, Ciancia, Rosanna, additional, Orsucci, Lorella, additional, Pinto, Antonello, additional, Usai, Sara Veronica, additional, Arcari, Annalisa, additional, Ilariucci, Fiorella, additional, Rossi, Francesca Gaia, additional, Benedetti, Fabio, additional, Flenghi, Leonardo, additional, Ghiggi, Chiara, additional, Molinari, Anna Lia, additional, Stefoni, Vittorio, additional, Volpetti, Stefano, additional, Zilioli, Vittorio Ruggero, additional, Ballerini, Filippo, additional, Bruna, Riccardo, additional, Cavallo, Federica, additional, Musuraca, Gerardo, additional, Patti, Caterina, additional, Re, Francesca, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Zanni, Manuela, additional, Dodero, Anna, additional, Pileri, Stefano A, additional, Ciccone, Giovannino, additional, and Corradini, Paolo, additional

Published
2021
Full Text
View/download PDF

27. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Molica, Stefano, Ilariucci, Fiorella, Mauro, Francesca R., Di Renzo, Nicola, Di Raimondo, Francesco, Vincelli, Iolanda, Todoerti, Katia, Matis, Serena, Musolino, Caterina, Fabris, Sonia, Lionetti, Marta, Levato, Luciano, Zupo, Simona, Angrilli, Francesco, Consoli, Ugo, Festini, Gianluca, Longo, Giuseppe, Cortelezzi, Agostino, Musto, Pellegrino, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2016
Full Text
View/download PDF

28. Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study

Author

Morabito, Fortunato, Cutrona, Giovanna, Gentile, Massimo, Fabris, Sonia, Matis, Serena, Vigna, Ernesto, Todoerti, Katia, Colombo, Monica, Recchia, Anna G., Bossio, Sabrina, De Stefano, Laura, Ilariucci, Fiorella, Cortelezzi, Agostino, Consoli, Ugo, Vincelli, Iolanda, Pesce, Emanuela A., Musolino, Caterina, Molica, Stefano, Di Raimondo, Francesco, Neri, Antonino, and Ferrarini, Manlio

Published
2015
Full Text
View/download PDF

29. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Author

Ferreri, Andrés JM, Reni, Michele, Foppoli, Marco, Martelli, Maurizio, Pangalis, Gerasimus A, Frezzato, Maurizio, Cabras, Maria Giuseppina, Fabbri, Alberto, Corazzelli, Gaetano, Ilariucci, Fiorella, Rossi, Giuseppe, Soffietti, Riccardo, Stelitano, Caterina, Vallisa, Daniele, Zaja, Francesco, Zoppegno, Lucía, Aondio, Gian Marco, Avvisati, Giuseppe, Balzarotti, Monica, Brandes, Alba A, Fajardo, José, Gomez, Henry, Guarini, Attilio, Pinotti, Graziella, Rigacci, Luigi, Uhlmann, Catrina, Picozzi, Piero, Vezzulli, Paolo, Ponzoni, Maurilio, Zucca, Emanuele, Caligaris-Cappio, Federico, and Cavalli, Franco

Published
2009
Full Text
View/download PDF

30. Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy

Author

Gozzi, Fabrizio, primary, Aldigeri, Raffaella, additional, Mastrofilippo, Valentina, additional, De Simone, Luca, additional, Bolletta, Elena, additional, Marzano, Jacopo, additional, Iannetta, Danilo, additional, Coassin, Marco, additional, Ilariucci, Fiorella, additional, Ferrari, Angela, additional, Luminari, Stefano, additional, Merli, Francesco, additional, Croci, Stefania, additional, Zerbini, Alessandro, additional, Farnetti, Enrico, additional, Nicoli, Davide, additional, Valli, Riccardo, additional, Tamagnini, Ione, additional, Cavazza, Alberto, additional, Salvarani, Carlo, additional, Fontana, Luigi, additional, and Cimino, Luca, additional

Published
2021
Full Text
View/download PDF

31. A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Author

Scarfo, Lydia, Coscia, Marta, Molteni, Alfredo, Rambaldi, Alessandro, Marasca, Roberto, Steffanoni, Sara, Murru, Roberta, Maschio, Nilla, Scortechini, Ilaria, Gambacorti-Passerini, Carlo, Pennese, Elsa, Trentin, Livio, Moia, Riccardo, Farina, Lucia, Innao, Vanessa, Musto, Pellegrino, Sanna, Alessandro, Facchinelli, Davide, Falcucci, Paolo, Pini, Massimo, Laurenti, Luca, Varettoni, Marzia, Angeletti, Ilaria, Orsucci, Lorella, Rago, Angela, D'Arena, Giovanni, Melillo, Lorella Maria Antonia, Maggi, Alessandro, Ilariucci, Fiorella, Massaia, Massimo, Pastore, Domenico, Vallisa, Daniele, Fazi, Paola, Piciocchi, Alfonso, Messina, Monica, Paoloni, Francesca Paola, Foà, Robin, Del Giudice, Ilaria, Rigolin, Gian Matteo, Cuneo, Antonio, and Ghia, Paolo

Published
2023
Full Text
View/download PDF

32. 36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Author

Mauro, Francesca Romana, Della Starza, Irene, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Gaidano, Gianluca, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Stelitano, Caterina, Mannina, Donato, Ilariucci, Fiorella, Massaia, Massimo, Rigolin, Gian Matteo, Scarfo, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Belsito Patrizi, Valeria, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pepe, Sara, Andriola, Costanza, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, and Foà, Robin

Published
2023
Full Text
View/download PDF

33. Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas‘

Author

Mauro, Francesca Romana, Reda, Gianluigi, Arena, Valentina, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Laurenti, Luca, Gaidano, Gianluca, Marasca, Roberto, Orsucci, Lorella, Murru, Roberta, Stelitano, Caterina, Ilariucci, Fiorella, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfo, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Califano, Catello, Gottardi, Daniela, Liberati, Anna Marina, Pietrasanta, Daniela, Molica, Stefano, Cassin, Ramona, Visentin, Andrea, Vitale, Candida, Lapietra, Gianfranco, Della Starza, Irene, De Propris, Maria Stefania, Raponi, Sara, Nanni, Mauro, Del Giudice, Ilaria, Giuliani, Giorgia, Vignetti, Marco, Guarini, Anna, Albano, Francesco, Neri, Antonino, Cuneo, Antonio, and Foà, Robin

Published
2020
Full Text
View/download PDF

34. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Mosca, Laura, Matis, Serena, Fabris, Sonia, Lionetti, Marta, Ilariucci, Fiorella, Zupo, Simona, Musolino, Caterina, Levato, Luciano, Molica, Stefano, Di Raimondo, Francesco, Vincelli, Iolanda, Di Rienzo, Nicola, Pesce, Emanuela Anna, Angrilli, Francesco, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2014
Full Text
View/download PDF

35. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications

Author

Lionetti, Marta, Fabris, Sonia, Cutrona, Giovanna, Agnelli, Luca, Ciardullo, Carmela, Matis, Serena, Ciceri, Gabriella, Colombo, Monica, Maura, Francesco, Mosca, Laura, Gentile, Massimo, Recchia, Anna G., Ilariucci, Fiorella, Musolino, Caterina, Molica, Stefano, Di Raimondo, Francesco, Cortelezzi, Agostino, Rossi, Davide, Gaidano, Gianluca, Morabito, Fortunato, Ferrarini, Manlio, and Neri, Antonino

Published
2014
Full Text
View/download PDF

37. Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy.

Author

Gozzi, Fabrizio, Aldigeri, Raffaella, Mastrofilippo, Valentina, De Simone, Luca, Bolletta, Elena, Marzano, Jacopo, Iannetta, Danilo, Coassin, Marco, Ilariucci, Fiorella, Ferrari, Angela, Luminari, Stefano, Merli, Francesco, Croci, Stefania, Zerbini, Alessandro, Farnetti, Enrico, Nicoli, Davide, Valli, Riccardo, Tamagnini, Ione, Cavazza, Alberto, and Salvarani, Carlo

Subjects
CANCER chemotherapy, SURVIVAL rate, UVEITIS, LYMPHOMAS, CENTRAL nervous system
Abstract

To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL). Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group. Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE±10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P =.03) and death (r = 0.56, P =.009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04– 0.85]) in the entire cohort. Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment.

Author

Dubbini, Maria Vittoria, De Marco, Loredana, Baldi, Licia, Vignolo, Luana, and Ilariucci, Fiorella

Subjects
COLITIS, ANAPLASTIC large-cell lymphoma, DRUG side effects, HODGKIN'S disease
Abstract

Given the hypothesis and considering the characteristics of apoptotic colitis, like that which develops in cases of graft-versus-host-disease or anti-PD-L1 therapy, high-dose steroid therapy with 1 mg/kg methylprednisolone was set [[4], [6]]. Targeted cancer therapies have become an attractive option for treating numerous malignancies. [Extracted from the article]

Published
2023
Full Text
View/download PDF

39. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Fabris, Sonia, Pesce, Emanuela Anna, Baldini, Luca, Di Raimondo, Francesco, Musolino, Caterina, Di Tonno, Paolo, Di Renzo, Nicola, Molica, Stefano, Brugiatelli, Maura, Ilariucci, Fiorella, Zupo, Simona, Matis, Serena, Maura, Francesco, Vigna, Ernesto, Angrilli, Francesco, Recchia, Anna Grazia, Quarta, Giovanni, Iannitto, Emilio, Fragasso, Alberto, Musto, Pellegrino, Spriano, Mauro, Vincelli, Iolanda, Vallisa, Daniele, Cortelezzi, Agostino, Mauro, Francesca Romana, Foà, Robin, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2013
Full Text
View/download PDF

40. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia

Author

Fabris, Sonia, Mosca, Laura, Cutrona, Giovanna, Lionetti, Marta, Agnelli, Luca, Ciceri, Gabriella, Barbieri, Marzia, Maura, Francesco, Matis, Serena, Colombo, Monica, Gentile, Massimo, Recchia, Anna Grazia, Anna Pesce, Emanuela, Di Raimondo, Francesco, Musolino, Caterina, Gobbi, Marco, Di Renzo, Nicola, Mauro, Francesca Romana, Brugiatelli, Maura, Ilariucci, Fiorella, Lipari, Maria Grazia, Angrilli, Francesco, Consoli, Ugo, Fragasso, Alberto, Molica, Stefano, Festini, Gianluca, Vincelli, Iolanda, Cortelezzi, Agostino, Federico, Massimo, Morabito, Fortunato, Ferrarini, Manlio, and Neri, Antonino

Published
2013
Full Text
View/download PDF

41. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

Author

Merli, Francesco, Luminari, Stefano, Ilariucci, Fiorella, Petrini, Mario, Visco, Carlo, Ambrosetti, Achille, Stelitano, Caterina, Caracciolo, Francesco, Di Renzo, Nicola, Angrilli, Francesco, Carella, Angelo M., Capodanno, Isabella, Barbolini, Elisa, Galimberti, Sara, and Federico, Massimo

Published
2012
Full Text
View/download PDF

43. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Author

Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Rivas, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marcos, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Lukas, Schuh, Anna, Eyre, Toby A, Kennedy, Ben, Bowles, Kris M, Vignetti, Marco, de la Serna, Javier, Moreno, Carol, Foà, Robin, Ghia, Paolo, GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum, Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Riva, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marco, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Luka, Schuh, Anna, Eyre, Toby A., Kennedy, Ben, Bowles, Kris M., Vignetti, Marco, De La Serna, Javier, Moreno, Carol, Foà, Robin, and Ghia, Paolo

Subjects
Oncology, Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study, Salvage therapy, chemistry.chemical_compound, rituximab, 0302 clinical medicine, Piperidines, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Aged, 80 and over, education.field_of_study, clinical trial, Hematology, Middle Aged, Prognosis, Fludarabine, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, Ibrutinib, Bendamustine, Retreatment, Rituxima, Rituximab, medicine.drug, Chronic Lymphocytic Leukemia, bendamustine, ibrutinib, Adult, medicine.medical_specialty, Population, NO, 03 medical and health sciences, Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, Chemoimmunotherapy, CLL, Bendamustine, Rituxima, prognosis, Hematology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Progression-free survival, education, Aged, Salvage Therapy, business.industry, Adenine, ERIC and UK CLL FORUM study, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, United Kingdom, Regimen, Pyrimidines, chemistry, chronic lymphocytic leukemia, Pyrazoles, prognosis, business, CLL, 030215 immunology
Abstract

We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del (17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion. (Registered at clinicaltrials.gov identifier: 02491398).

Published
2018

45. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study

Author

Bomben, Riccardo, Dal Bo, Michele, Capello, Daniela, Forconi, Francesco, Maffei, Rossana, Laurenti, Luca, Rossi, Davide, Del Principe, Maria Ilaria, Zucchetto, Antonella, Bertoni, Francesco, Rossi, Francesca Maria, Bulian, Pietro, Cattarossi, Ilaria, Ilariucci, Fiorella, Sozzi, Elisa, Spina, Valeria, Zucca, Emanuele, Degan, Massimo, Lauria, Francesco, Del Poeta, Giovanni, Efremov, Dimitar G., Marasca, Roberto, Gaidano, Gianluca, and Gattei, Valter

Published
2009

46. Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenströmʼs Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System

Author

Baldini, Luca, Goldaniga, Maria, Guffanti, Andrea, Broglia, Chiara, Cortelazzo, Sergio, Rossi, Andrea, Morra, Enrica, Colombi, Mariangela, Callea, Vincenzo, Pogliani, Enrico, Ilariucci, Fiorella, Luminari, Stefano, Morel, Pierre, Merlini, Giampaolo, and Gobbi, Paolo

Published
2005
Full Text
View/download PDF

47. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’

Author

Ferreri, Andrés J. M., Campo, Elías, Seymour, John F., Willemze, Rein, Ilariucci, Fiorella, Ambrosetti, Achille, Zucca, Emanuele, Rossi, Giuseppe, López-Guillermo, Armando, Pavlovsky, Miguel A., Geerts, Marie-Louise, Candoni, Anna, Lestani, Maurizio, Asioli, Silvia, Milani, Mario, Piris, Miguel A., Pileri, Stefano, Facchetti, Fabio, Cavalli, Franco, and Ponzoni, Maurilio

Published
2004

48. Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial

Author

Marchetti, Monia, Barosi, Giovanni, Balestri, Francesca, Viarengo, Gianluca, Gentili, Sara, Barulli, Sara, Demory, Jean-Loup, Ilariucci, Fiorella, Volpe, Antonio, Bordessoule, Dominique, Grossi, Alberto, Le Bousse-Kerdiles, Marie Caroline, Caenazzo, Andrea, Pecci, Alessandro, Falcone, Antonietta, Broccia, Giorgio, Bendotti, Cesarina, Bauduer, Fredric, Buccisano, Francesco, and Dupriez, Brigitte

Published
2004
Full Text
View/download PDF

49. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi

Author

Morabito, Fortunato, Gallamini, Andrea, Stelitano, Caterina, Callea, Vincenzo, Guglielmi, Cesare, Neri, Santo, Lazzaro, Antonio, Orsucci, Lorella, Ilariucci, Fiorella, Sacchi, Stefano, Vitolo, Umberto, and Federico, Massimo

Subjects
T cells -- Comparative analysis, T cells -- Patient outcomes, B cells -- Comparative analysis, B cells -- Patient outcomes, Lymphocytes -- Histology, Lymphocytes -- Comparative analysis, Lymphocytes -- Patient outcomes, Health
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results